The Emerging Role of Complement C3 as A Biomarker of Insulin Resistance and Cardiometabolic Diseases: Preclinical and Clinical Evidence

Publisher： Bentham Science Publishers

E-ISSN： 1876-1038|13|1|61-68

ISSN： 1574-8871

Source： Reviews on Recent Clinical Trials, Vol.13, Iss.1, 2018-01, pp. : 61-68

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Review: Neuroinflammatory pathways as treatment targets and biomarker candidates in epilepsy: emerging evidence from preclinical and clinical studies

By  

NEUROPATHOLOGY & APPLIED NEUROBIOLOGY, Vol. 44, Iss. 1, 2018-02 ,pp. : 91-111

John Wiley & Sons Inc

Access to resources Recommend Favorite

Galectin‐3: an emerging biomarker in stroke and cerebrovascular diseases

By  

EUROPEAN JOURNAL OF NEUROLOGY, Vol. 25, Iss. 2, 2018-02 ,pp. : 238-246

John Wiley & Sons Inc

Access to resources Recommend Favorite

Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data

By  

Oncology Research and Treatment, Vol. 38, Iss. 6, 2015-05 ,pp. : 291-298

Karger

Access to resources Recommend Favorite

Does liver-derived ANGPTL3 play a role in cardiometabolic risk? Current evidence and future perspectives

By Maranghi Marianna   Tiseo Giusy   Arca Marcello  

Clinical Lipidology, Vol. 8, Iss. 6, 2013-12 ,pp. : 615-618

Future Medicine

Access to resources Recommend Favorite

Insulin glulisine: preclinical hallmarks and clinical efficacy

By Schliess Freimut   Heise Tim  

Therapy, Vol. 6, Iss. 2, 2009-03 ,pp. : 209-229

Future Medicine

Access to resources Recommend Favorite